Member Info for Basser1

Nice find Krone. Glover was certainly very upbeat about SRA 737 being at the cornerstone of Cancer treatment. So many top notch science papers came out after this suggesting SRA 737 would be even more effective in combination. It became too big to cope with given Sierra finances and as such it was shelved. Well we will not have that problem with GSK.

I’ve posted most of this before but no harm in some re-inforcement, especially for any newbies.

List of Solid Tumour Cancers

Bladder Cancer
Breast Cancer
Cervical Cancer
Colon and Rectal Cancer
Endometrial Cancer
Kidney Cancer
Lip and Oral Cancer
Liver Cancer
Melanoma
Mesothelioma
Non Small Cell Lung Cancer
Non Melanoma Skin Cancer
Oral Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Sarcoma
Small Cell Lung Cancer
Thyroid Cancer

The Global Solid Tumour treatment market was valued at 121.3 billion dollars in 2018 and is expected to reach 424.6 Billion Dollars by 2027.

John Reader, Chief Scientific Officer at Sareum “ We are encouraged to see yet another potential treatment modality for SRA 737, in this case in tumours with a TP 53 mutation, a mutation that is present in approximately half of all solid tumour cancers”.

Tim Mitchell quote in RNS
The possible initiation of combination studies by Sierra Oncology including SRA 737 in the first half of 2022 is very encouraging and would represent a significant advance in the development of the SRA 737 programme. We look forward to the further update on the clinical development of SRA 737, a molecule that has shown great promise in clinical trials and pre- clinical studies, particularly in combination with other types of cancer therapy.

This in my view is why GSK has paid 55 dollars a share for Sierra Oncology. I would expect that they are will be eager to move forward as soon as the deal is sealed. There may be scope to initiate fast track status for some trials where there are unmet clinical needs such as Anogenital Cancer. GSK have the the funding. The merger securing Sierra staff with experience of SRA 737 is an added bonus. GLA

Hi Potnak
Sareum seem very keen on a Covid 19 trial for SDC 1801. On your timetable it would have to be done before the end of the year and if successful could greatly enhance any licence deal for 1801. Either that or the licence deal adequately reflects a future Covid trial that could become very successful. Either way the deal must reflect that Covid 19 trial could be successful

Sell at 229.50 gone thru..

https://quantisnow.com/i/2895854?utm_source=stocktwits

Interestingly the focus is on JAK1 as it has been found in clinical trials that it reduces itching.far better than the other JAKs.

I understand that Xentuzamab is owned by Eli Lilly. Interesting to note that it is at a phase 1/2 clinical stage for the treatment of prostate Cancer. So maybe there could be another opportunity for SRA737 combination at some stage.

Celtic - and GSK will be ecstatic in my opinion. It"s party time. After all I’m convinced it was SRA 737 they were after and they have got it for a steal in my view. On the other hand, Sierra shareholders have been badly let down . Sareum has suffered as well with long delays in progressing SRA737. But at least now we can see a clear path forward without further delay. The global Solid tumour treatment market was valued at 121.3 Billion dollars in 2018 and is expected to reach 424.6 billion dollars by 2027. With a bit of luck SRA737 can play a massive part in making the most of this growth - and providing much improved outcomes for Cancer sufferers. GLA

Sorry Schek!

Schedule - OK it was two days before this year started so quite recent really. But it’s just another scientific paper over the last two years that has pointed out SRA 737s potential in treating cancer in combination. The shame is that Sierra new this but hid it away. They didn’t even mention it in the merger with GSK press releases. Absolute disgrace. But we move on.

https://www.guidelines.co.uk/news/uk-researchers-find-way-to-boost-emerging-breast-cancer-drugs-effectiveness/456673.article

Had not seen this before. Apologies if already posted.

https://newsfilter.io/a/2fe1adcaa6a3e0eb78da7311973844b6

Another 11 employees taken on. Sierra are not sitting on their backside.

Lazarus - that’s very interesting. I suppose the big question is will it be a merger deal with Sareum Holdings being an indirect wholly owned subsidiary ie similar to the Sierra arrangements. That would seem to me to be very attractive to the big pharmas in terms of stability and ongoing expertise in the latest autoimmune and Cancer treatments.

Apologies SDC1801

Deadline fast approaching for the submission of the SDC1802 Clinical Trial Application. Should there be interested parties in negotiations with Sareum and they want to influence the autoimmune indications for the trials, I presume there would have to be an announcement fairly soon.

There were some big buys today. That’s what I call smart money. Confident that will continue.

Ahfam I would expect Sierra to be carrying on as normal - why would they wait to submit Momelotinib for FDA approval and why wouldn’t they continue to talk to interested parties on SRA 737 combos. They can make a lot of behind the scenes progress in moving potential plans forward in the time period before the merger is sealed. I am sure that’s what GSK would want. They would be stupid if they did not want that to happen. The problem on Aim is that too many people are in too much of a rush. They need a naughty class course from Warren Buffet.

Dilley needs up to 20 combo trials to cover all solid tumour cancers - 50% of which are susceptible to SRA 737 lethality due to. TP53 gene mutation. That’s a lot of trials and lots of income for GSK for a bargain.

Nice summing up Oracle! With GSK finances behind it we should have SRA 737 up and running sooner than we think - especially as it looks like Dilley has already been speaking to potential partners for combo trials.

Desamax - Party G was not a buyer but was pursuing future partnerships with Sierra to possibly undergo potential joint clinical trials. This is still relevant in my view as Under the terms of the GSK takeover, Sierra Oncology will become an indirect wholly owned subsidiary of GSK. It will not cease to exist although it will not have any shareholding. It is reasonable to suppose that Sierra Oncology in its new capacity will lead further development of its current pipeline assets including SRA 737 - but of course with GSK agreeing strategy and closely overseeing progress. That seems to makes sense given the number of staff Sierra has recruited over the last year and who now will be familiar and gaining experience with the pipeline. Happy for further views on any of this.